## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC Form 6-K July 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 18 July 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with

them ('PCA')

a) Name Ms C Thomas b) Position/status SVP, HR

c) Initial notification/amendment

Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction

monitor

a) Name GlaxoSmithKline plc

b)LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of

3. transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')
ISIN: GB0009252882

Description of

a) the financial instrument

Increase in notional interest in Ordinary Shares following

the re-investment of dividends paid to

b) Nature of the transaction

shareholders on 14 July 2016, on Ordinary Shares held in the Company's Deferred Investment Award

Programme.

c) Price(s) and volume(s)

Price(s) Volume(s) £16.4900 363.463 n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction

2016-07-14

f) Place of the transaction

n/a

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: July 18, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc